Figure 3. Effect of treatment of simvastatin, ezetimibe, U18666A, or sphingosine kinase inhibitor (SKI) on survival of WT-HFE and C282Y-HFE stably transfected human neuroblastoma cells.

WT-HFE (2.4–3×10⁴/well of a 96 well plate) or C282Y-HFE (0.8–1.5×10⁴/well) stably transfected SH-SY5Y cells were cultured overnight in complete medium (10% FBS). After washing the cells with Hank’s buffer, they were exposed to different concentrations of either simvastatin (A), U18666A (B), ezetimibe (C), or SKI (D) in 1% FBS-containing medium and incubated at 37°C in an atmosphere of 5% CO₂/95% air for 48 hr. At the end of that time, cell survival was measured using the MTS assay. Vehicle (1% DMSO) treated cells served as the 100% control. This is representative data of 3 different experiments. Data are displayed as means ± SEM. Some error bars are too small to be seen. The asterisk indicates a significant difference compared to controls. *p<0.05, **p<0.01, ***p<0.001 (n = 3).